A nationwide retrospective study of malignant tumors arising from ovarian mature teratoma in Japa

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

The individual or family member has clearly expressed a refusal to opt out. The researcher considers it inappropriate, citing difficulties in obtaining data.

Study & Design

Study Type: Others,meta-analysis etc

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 4/22/2024

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 9/9/2024

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 7/6/2020

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 9/18/2023

Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

WithdrawnPhase 2

Bristol-Myers Squibb

Updated 4/15/2024

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 8/10/2020

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 3/2/2022

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 5/2/2022

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

Bristol-Myers Squibb International Corporation

Updated 4/5/2021

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Phase 1

BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO

Updated 4/5/2021

A nationwide retrospective study of malignant tumors arising from ovarian mature teratoma in Japa

Recruitment & Eligibility

Study & Design

Related Trials

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatio

Clinical Trial Alerts

Clinical Trial Alerts